Results 121 to 130 of about 1,814 (132)

Brolucizumab in polypoidal choroidal vasculopathy

Expert Opinion on Biological Therapy, 2022
Nilesh Kumar, Anat Loewenstein, Ashish Sharma   +2 more
exaly  

Detection and Management of Intraocular Inflammation after Brolucizumab Treatment for Neovascular Age-Related Macular Degeneration

Ophthalmology Retina, 2023
Ramin Tadayoni, Bahram Bodaghi, Laurent Kodjikian   +2 more
exaly  

Intravitreal Brolucizumab and Aflibercept for Polypoidal Choroidal Vasculopathy

Journal of Ocular Pharmacology and Therapeutics, 2023
Han Joo Cho, Chul Gu Kim
exaly  

Brolucizumab: a novel anti-VEGF humanized single-chain antibody fragment for treating w-AMD

Expert Opinion on Biological Therapy, 2021
Carlo Traverso, Massimo Nicolò, Ferro Desideri Lorenzo   +2 more
exaly  

Three cases of brolucizumab-associated retinal vasculitis treated with systemic and local steroid therapy

Japanese Journal of Ophthalmology, 2021
Yasuki Itô, Keiko Kataoka, Yuyako Nakano   +2 more
exaly  

<p>Brolucizumab: evidence to date in the treatment of neovascular age-related macular degeneration</p>

Clinical Ophthalmology, 2019
K Bailey Freund, Nicolas A Yannuzzi
exaly  

Safety and Efficacy of Brolucizumab in the Treatment of Diabetic Macular Edema and Diabetic Retinopathy: A Systematic Review and Meta-Analysis

Seminars in Ophthalmology
Ayman G Elnahry, Basel Abdelazeem, Abdelaziz Abdelaal   +2 more
exaly  

Side Effects of Brolucizumab

Journal of Ophthalmic and Vision Research
Saeed Mohammadi, Tahmineh Motevasseli, William Freeman   +2 more
exaly  

Adverse events associated with brolucizumab: a disproportionality analysis of the FDA adverse event reporting system (FAERS)

Expert Opinion on Drug Safety
Taomin Huang
exaly  

Treatment of neovascular age-related macular degeneration: one year real-life results with intravitreal Brolucizumab

Frontiers in Medicine
Maria Consiglia Trotta
exaly